CD4 and hepatocellular carcinoma: Nevertheless, our data here show that SCARF1 could potentially support the recruitment of proinflammatory (CD4+CD25−) T cells to HCC tumors, leading to decreased tumoral progression and, ultimately, a better overall outcome (Figure 6).